Drug Profile
PAS 393
Alternative Names: PAS-393Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Pascal Biosciences; University of British Columbia
- Class Antineoplastics; Cannabinoids; Immunotherapies; Terpenes
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in Canada
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 14 Sep 2020 Pascal Biosciences and SōRSE Technology Corporation agree to co-develop PAS 393 for solid tumours